Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

NRAS mutant melanoma--undrugable?

Oncotarget - 1 Apr 2013

Posch Christian, Ortiz-Urda Susana

Abstract excerpt

Mutations in the three rat sarcoma (RAS) family members NRAS (neuroblastoma-RAS), HRAS (Harvey-RAS) and KRAS (Kirsten-RAS) are found in one third of human cancers. Among the first oncogenes discovered in cutaneous melanoma was NRAS, which is mutant in up to 20% of tumors causing aberrant signaling in several downstream cascades. Despite, being a highly relevant therapeutic target, design of small molecules...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to HRAS gene
Share to KRAS gene
Share to NRAS gene

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Melanoma

Share to Mutation

Share to Proto-Oncogene Proteins p21(ras)

Share to Signal Transduction

Source

Open in PubMed Open full text

Identifiers

PMID: 23660168
DOI: 10.18632/oncotarget.970
PMCID: PMC3720596

Genes

NRAS
HRAS
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

NRAS mutant melanoma--undrugable?PMID 23660168Read ↗

NRAS mutant melanoma: Towards better therapies.Semantic proximity Read ↗

Current Perspectives and Novel Strategies of NRAS-Mutant MelanomaSemantic proximity Read ↗

Targeting mutant NRAS signaling pathways in melanoma.Semantic proximity Read ↗

Nras in melanoma: targeting the undruggable target.Semantic proximity Read ↗

Targeting the MAPK pathway for NRAS mutant melanoma: from mechanism to clinic.Semantic proximity Read ↗

Targeting NRAS in melanoma.Semantic proximity Read ↗

MicroRNA-708 emerges as a potential candidate to target undruggable NRAS.Semantic proximity Read ↗

<em>NRAS</em>-mutant melanoma: current challenges and future prospectSemantic proximity Read ↗

Insights into RAS-driven melanoma and its therapeutic implications.Semantic proximity Read ↗

NRAS mutant melanoma: biological behavior and future strategies for therapeutic management.Semantic proximity Read ↗

Inhibition and degradation of NRAS with a pan-NRAS monobody.Semantic proximity Read ↗

NRAS-mutant melanoma: response to chemotherapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.